Cargando…
Tildrakizumab in the treatment of psoriasis – literature review
Psoriasis is a chronic, inflammatory disease. The incidence of its occurrence in developed countries is 1–4%. The aim of this study is to present the current state of knowledge and characterize the antibody tildrakizumab, which in March 2018 was approved by the FDA agency for use in adult patients w...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753595/ https://www.ncbi.nlm.nih.gov/pubmed/31548750 http://dx.doi.org/10.5114/reum.2019.87620 |